Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases
Autoimmune disease development depends on multiple factors, including genetic and environmental. Abnormalities such as sialylation levels and/or quality have been recently highlighted. The adjunction of sialic acid at the terminal end of glycoproteins and glycolipids is essential for distinguishing...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/7/3402 |
| _version_ | 1797539935502204928 |
|---|---|
| author | Anne Bordron Marie Morel Cristina Bagacean Maryvonne Dueymes Pierre Pochard Anne Harduin-Lepers Christophe Jamin Jacques-Olivier Pers |
| author_facet | Anne Bordron Marie Morel Cristina Bagacean Maryvonne Dueymes Pierre Pochard Anne Harduin-Lepers Christophe Jamin Jacques-Olivier Pers |
| author_sort | Anne Bordron |
| collection | DOAJ |
| description | Autoimmune disease development depends on multiple factors, including genetic and environmental. Abnormalities such as sialylation levels and/or quality have been recently highlighted. The adjunction of sialic acid at the terminal end of glycoproteins and glycolipids is essential for distinguishing between self and non-self-antigens and the control of pro- or anti-inflammatory immune reactions. In autoimmunity, hyposialylation is responsible for chronic inflammation, the anarchic activation of the immune system and organ lesions. A detailed characterization of this mechanism is a key element for improving the understanding of these diseases and the development of innovative therapies. This review focuses on the impact of sialylation in autoimmunity in order to determine future treatments based on the regulation of hyposialylation. |
| first_indexed | 2024-03-10T12:52:53Z |
| format | Article |
| id | doaj.art-0e66d47f3fba49df8527c620c2dc2df0 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T12:52:53Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-0e66d47f3fba49df8527c620c2dc2df02023-11-21T12:06:05ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-03-01227340210.3390/ijms22073402Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune DiseasesAnne Bordron0Marie Morel1Cristina Bagacean2Maryvonne Dueymes3Pierre Pochard4Anne Harduin-Lepers5Christophe Jamin6Jacques-Olivier Pers7Univ Brest, Inserm, LBAI, UMR1227 Brest, FranceUniv Brest, Inserm, LBAI, UMR1227 Brest, FranceUniv Brest, Inserm, LBAI, UMR1227 Brest, FranceUniv Brest, Inserm, LBAI, UMR1227 Brest, FranceCHU de Brest, Laboratory of Immunolgy, 29200 Brest, FranceUniv. Lille, CNRS UMR 8576—UGSF—Unité de Glycobiologie Structurale et Fonctionnelle, 59000 Lille, FranceUniv Brest, Inserm, LBAI, UMR1227 Brest, FranceUniv Brest, Inserm, LBAI, UMR1227 Brest, FranceAutoimmune disease development depends on multiple factors, including genetic and environmental. Abnormalities such as sialylation levels and/or quality have been recently highlighted. The adjunction of sialic acid at the terminal end of glycoproteins and glycolipids is essential for distinguishing between self and non-self-antigens and the control of pro- or anti-inflammatory immune reactions. In autoimmunity, hyposialylation is responsible for chronic inflammation, the anarchic activation of the immune system and organ lesions. A detailed characterization of this mechanism is a key element for improving the understanding of these diseases and the development of innovative therapies. This review focuses on the impact of sialylation in autoimmunity in order to determine future treatments based on the regulation of hyposialylation.https://www.mdpi.com/1422-0067/22/7/3402sialic acidsialyltransferaseautoimmune diseasesimmunoglobulinCD22therapies |
| spellingShingle | Anne Bordron Marie Morel Cristina Bagacean Maryvonne Dueymes Pierre Pochard Anne Harduin-Lepers Christophe Jamin Jacques-Olivier Pers Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases International Journal of Molecular Sciences sialic acid sialyltransferase autoimmune diseases immunoglobulin CD22 therapies |
| title | Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases |
| title_full | Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases |
| title_fullStr | Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases |
| title_full_unstemmed | Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases |
| title_short | Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases |
| title_sort | hyposialylation must be considered to develop future therapies in autoimmune diseases |
| topic | sialic acid sialyltransferase autoimmune diseases immunoglobulin CD22 therapies |
| url | https://www.mdpi.com/1422-0067/22/7/3402 |
| work_keys_str_mv | AT annebordron hyposialylationmustbeconsideredtodevelopfuturetherapiesinautoimmunediseases AT mariemorel hyposialylationmustbeconsideredtodevelopfuturetherapiesinautoimmunediseases AT cristinabagacean hyposialylationmustbeconsideredtodevelopfuturetherapiesinautoimmunediseases AT maryvonnedueymes hyposialylationmustbeconsideredtodevelopfuturetherapiesinautoimmunediseases AT pierrepochard hyposialylationmustbeconsideredtodevelopfuturetherapiesinautoimmunediseases AT anneharduinlepers hyposialylationmustbeconsideredtodevelopfuturetherapiesinautoimmunediseases AT christophejamin hyposialylationmustbeconsideredtodevelopfuturetherapiesinautoimmunediseases AT jacquesolivierpers hyposialylationmustbeconsideredtodevelopfuturetherapiesinautoimmunediseases |